Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Body Mass Index, Sarcopenia and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.

Tressie Herrmann,Cécile Mione,Pierre-François Montoriol,Ioana Molnar,Angeline Ginzac,Xavier Durando,Hakim Mahammedi

Oncology（2021）

Cited 8|Views3
No score
Abstract
This trial showed that a higher BMI and weight gain during nivolumab treatment were good predictive markers for outcomes in mRCC with nivolumab. Sarcopenia and variations in SMI could thus be of interest, but further studies are required.
More
Translated text
Key words
Weight change, Sarcopenia, Renal carcinoma, Nivolumab, Predictive markers
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined